Literature DB >> 12742228

Inhibition of Ca(2+) signalling by the sphingosine 1-phosphate receptor S1P(1).

Dagmar Meyer zu Heringdorf1, Myriam E M Vincent, Matthias Lipinski, Kerstin Danneberg, Udo Stropp, De-an Wang, Gabor Tigyi, Karl H Jakobs.   

Abstract

The lysophospholipid, sphingosine 1-phosphate (S1P), regulates a multitude of cellular functions by activating specific G protein-coupled receptors (GPCRs) (S1P(1-5), plus three newly identified S1P receptors). The G(i)-coupled S1P(1) receptor inhibits adenylyl cyclase, stimulates mitogen-activated protein kinases (MAP kinases) and cell migration, and is required for blood vessel maturation. Here, we report that S1P(1) inhibits Ca(2+) signalling in a number of cell types. In HEK-293 cells, which endogenously express S1P(1-3), overexpression of S1P(1) reduced intracellular free Ca(2+) concentration ([Ca(2+)](i)) increases induced by various receptor agonists as well as thapsigargin. The inhibitory Ca(2+) signalling of S1P(1) was blocked by pertussis toxin (PTX) and the protein kinase C (PKC) inhibitor, Gö6976, and imitated by phorbol ester and overexpression of classical PKC isoforms. Activation of S1P(1) stably expressed in RH7777 cells, which endogenously do not express S1P receptors, also inhibited Ca(2+) signalling, without mediating Ca(2+) mobilization on its own. It is concluded that the widely expressed S1P receptor S1P(1) inhibits Ca(2+) signalling, most likely via G(i) proteins and classical PKC isoforms. Co-expression of S1P(1) with S1P(3), but not S1P(2), reversed the inhibitory effect of S1P(1), furthermore suggesting a specific interplay of S1P receptor subtypes usually found within a single cell type.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12742228     DOI: 10.1016/s0898-6568(03)00011-1

Source DB:  PubMed          Journal:  Cell Signal        ISSN: 0898-6568            Impact factor:   4.315


  8 in total

Review 1.  cAMP guided his way: a life for G protein-mediated signal transduction and molecular pharmacology-tribute to Karl H. Jakobs.

Authors:  Klaus Aktories; Peter Gierschik; Dagmar Meyer Zu Heringdorf; Martina Schmidt; Günter Schultz; Thomas Wieland
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2019-05-17       Impact factor: 3.000

Review 2.  S1PR1 as a Novel Promising Therapeutic Target in Cancer Therapy.

Authors:  Narges Rostami; Afshin Nikkhoo; Amir Ajjoolabady; Gholamreza Azizi; Mohammad Hojjat-Farsangi; Ghasem Ghalamfarsa; Bahman Yousefi; Mehdi Yousefi; Farhad Jadidi-Niaragh
Journal:  Mol Diagn Ther       Date:  2019-08       Impact factor: 4.074

Review 3.  Signal transduction underlying the vascular effects of sphingosine 1-phosphate and sphingosylphosphorylcholine.

Authors:  Denise G Hemmings
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2006-04       Impact factor: 3.000

4.  A novel lipid natriuretic factor in the renal medulla: sphingosine-1-phosphate.

Authors:  Qing Zhu; Min Xia; Zhengchao Wang; Pin-Lan Li; Ningjun Li
Journal:  Am J Physiol Renal Physiol       Date:  2011-04-06

5.  Ablation of sphingosine kinase-2 inhibits tumor cell proliferation and migration.

Authors:  Peng Gao; Charles D Smith
Journal:  Mol Cancer Res       Date:  2011-09-06       Impact factor: 5.852

6.  Sphingosine-1-phosphate elicits receptor-dependent calcium signaling in retinal amacrine cells.

Authors:  Scott Crousillac; Jeremy Colonna; Emily McMains; Jill Sayes Dewey; Evanna Gleason
Journal:  J Neurophysiol       Date:  2009-09-23       Impact factor: 2.714

7.  Dual effects of daily FTY720 on human astrocytes in vitro: relevance for neuroinflammation.

Authors:  Celina Wu; Soo Y Leong; Craig S Moore; Qiao Ling Cui; Pavel Gris; Louis-Philippe Bernier; Trina A Johnson; Philippe Séguéla; Timothy E Kennedy; Amit Bar-Or; Jack P Antel
Journal:  J Neuroinflammation       Date:  2013-03-19       Impact factor: 8.322

8.  The novel sphingosine-1-phosphate receptors antagonist AD2900 affects lymphocyte activation and inhibits T-cell entry into the lymph nodes.

Authors:  Reuven Or; Osnat Almogi-Hazan; Jing Song; Arie Dagan; Zhanna Yakhtin; Shimon Gatt; Sean Riley; Hugh Rosen
Journal:  Oncotarget       Date:  2017-06-27
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.